Prosonix elects Ken Cunningham to board
This article was originally published in Scrip
Executive Summary
Prosonix, a pharmaceutical company developing a portfolio of respiratory medicines, has elected Dr Ken Cunningham to its board of directors as a non-executive director, and chair of its advisory board. Dr Cunningham is executive chairman of PolyTherics and until August 2010 was CEO of Skyepharma.